Cannabis as a substitute for prescription drugs - a cross-sectional study. 2017

James M Corroon, and Laurie K Mischley, and Michelle Sexton
Center for Medical Cannabis Education, Del Mar, CA.

BACKGROUND The use of medical cannabis is increasing, most commonly for pain, anxiety and depression. Emerging data suggest that use and abuse of prescription drugs may be decreasing in states where medical cannabis is legal. The aim of this study was to survey cannabis users to determine whether they had intentionally substituted cannabis for prescription drugs. METHODS A total of 2,774 individuals were a self-selected convenience sample who reported having used cannabis at least once in the previous 90 days. Subjects were surveyed via an online anonymous questionnaire on cannabis substitution effects. Participants were recruited through social media and cannabis dispensaries in Washington State. RESULTS A total of 1,248 (46%) respondents reported using cannabis as a substitute for prescription drugs. The most common classes of drugs substituted were narcotics/opioids (35.8%), anxiolytics/benzodiazepines (13.6%) and antidepressants (12.7%). A total of 2,473 substitutions were reported or approximately two drug substitutions per affirmative respondent. The odds of reporting substituting were 4.59 (95% confidence interval [CI], 3.87-5.43) greater among medical cannabis users compared with non-medical users and 1.66 (95% CI, 1.27-2.16) greater among those reporting use for managing the comorbidities of pain, anxiety and depression. A slightly higher percentage of those who reported substituting resided in states where medical cannabis was legal at the time of the survey (47% vs. 45%, p=0.58), but this difference was not statistically significant. CONCLUSIONS These patient-reported outcomes support prior research that individuals are using cannabis as a substitute for prescription drugs, particularly, narcotics/opioids, and independent of whether they identify themselves as medical or non-medical users. This is especially true if they suffer from pain, anxiety and depression. Additionally, this study suggests that state laws allowing access to, and use of, medical cannabis may not be influencing individual decision-making in this area.

UI MeSH Term Description Entries

Related Publications

James M Corroon, and Laurie K Mischley, and Michelle Sexton
July 2021, Harm reduction journal,
James M Corroon, and Laurie K Mischley, and Michelle Sexton
December 2009, Harm reduction journal,
James M Corroon, and Laurie K Mischley, and Michelle Sexton
September 2020, Nederlands tijdschrift voor geneeskunde,
James M Corroon, and Laurie K Mischley, and Michelle Sexton
July 2019, JAMA,
James M Corroon, and Laurie K Mischley, and Michelle Sexton
September 2018, Annales pharmaceutiques francaises,
James M Corroon, and Laurie K Mischley, and Michelle Sexton
January 2019, Substance use & misuse,
James M Corroon, and Laurie K Mischley, and Michelle Sexton
July 2019, JAMA,
James M Corroon, and Laurie K Mischley, and Michelle Sexton
March 2021, Journal of family medicine and primary care,
James M Corroon, and Laurie K Mischley, and Michelle Sexton
October 2018, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)),
James M Corroon, and Laurie K Mischley, and Michelle Sexton
May 1985, Revue de l'infirmiere,
Copied contents to your clipboard!